+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genitourinary Drugs Market by Indication, Therapeutic Class, Distribution Channel, End User, Route Of Administration, Formulation, Sales Model - Global Forecast 2025-2030- Product Image
Genitourinary Drugs Market by Indication, Therapeutic Class, Distribution Channel, End User, Route Of Administration, Formulation, Sales Model - Global Forecast 2025-2030- Product Image
Sale

Genitourinary Drugs Market by Indication, Therapeutic Class, Distribution Channel, End User, Route Of Administration, Formulation, Sales Model - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5454847
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The genitourinary drugs market is experiencing dynamic growth based on evolving treatment paradigms, increased disease prevalence, and the integration of digital health tools. Decision-makers in the healthcare and pharmaceutical sectors face a landscape shaped by rapid innovation, supply chain shifts, and region-specific trends.

Market Snapshot: Genitourinary Drugs Market Growth

The genitourinary drugs market grew from USD 39.83 billion in 2024 to USD 41.54 billion in 2025. It is expected to continue growing at a CAGR of 4.21%, reaching USD 51.03 billion by 2030.

Scope & Segmentation of the Genitourinary Drugs Market

  • Indications: Benign Prostatic Hyperplasia, Erectile Dysfunction, Interstitial Cystitis, Overactive Bladder, Urinary Tract Infection
  • Therapeutic Classes: 5 Alpha Reductase Inhibitors, Alpha Blockers, Anticholinergics, Beta3 Agonists, Combination Therapies, PDE5 Inhibitors
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End Users: General Practice Clinics, Urology Clinics, Homecare, Secondary Care Centers, Specialty Clinics, Tertiary Care Centers
  • Routes of Administration: Injectable, Oral, Topical
  • Formulations: Capsules, Injectable Solutions, Oral Solutions, Tablets
  • Sales Models: Over-the-Counter (In-Store and Online), Prescription
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific; including specific markets in the United States, Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
  • Companies Analyzed: Pfizer Inc., Astellas Pharma Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Ferring International Center S.A., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co., Inc.

Key Takeaways

  • New digital health solutions and connected diagnostics are enabling real-time patient monitoring and personalized support, leading to greater adherence and optimized therapeutic outcomes.
  • Precision medicine and biomarker-driven strategies are advancing the development of biologics and combination therapies, supporting targeted treatment for diverse patient subgroups and reducing adverse event rates.
  • Open collaboration among pharmaceutical companies, research institutions, and technology innovators has accelerated early-stage development and helped reduce risk across the drug development lifecycle.
  • Adaptive clinical trial methodologies and regulatory flexibility are shortening the path from innovation to patient access, while maintaining strong safety and efficacy standards.
  • Regional adoption varies, with established healthcare systems prioritizing advanced therapeutics and digital integration, and emerging markets drawing increased investment in specialty clinics and localized manufacturing.

Tariff Impact and Supply Chain Considerations

  • The introduction of revised United States tariffs on imported pharmaceutical ingredients in 2025 is increasing cost pressure across the genitourinary segment, necessitating strategic supply chain adjustments such as near-shoring API production and vendor diversification.
  • Manufacturers and logistics providers face elevated operating costs, potential disruptions in lead times, and a need for proactive engagement with regulators to secure exemptions and maintain pricing competitiveness.
  • Healthcare payers are reassessing reimbursement frameworks as pricing dynamics shift, requiring robust stakeholder engagement to ensure continued patient access and product availability.

Methodology & Data Sources

This assessment utilizes a combination of primary interviews with market stakeholders, systematic secondary research, proprietary and public data analysis, and triangulation with expert opinion. Coverage includes qualitative insights and quantitative trends validated for consistency.

Why This Report Matters

  • Enables senior leadership to benchmark product strategies against evolving therapeutic trends and competitor moves across key global regions.
  • Supports tactical planning and procurement with up-to-date intelligence on market segmentation, regulatory developments, and pricing dynamics.
  • Provides actionable guidance for navigating tariff shifts, supporting innovation pipelines, and optimizing market access.

Conclusion

The genitourinary drugs market is evolving due to digital health adoption, regulatory changes, and market-specific factors. Stakeholders equipped with current, actionable insights will be best positioned to adapt strategies, manage risks, and unlock sustained value in this competitive landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of novel small interfering RNA therapies for overactive bladder management
5.2. Development and market penetration of once-monthly intramuscular testosterone replacement injections
5.3. Integration of genetic biomarkers and profiling in urinary tract infection treatment protocols
5.4. Escalating investment in biologic therapies targeting bladder lining inflammation in interstitial cystitis
5.5. Approval impact of sodium-glucose cotransporter 2 inhibitors on renal protection in diabetic nephropathy
5.6. Emergence of precision device drug-delivery combinations for male erectile dysfunction management
5.7. Expansion of telehealth platforms enabling remote diagnosis and prescription of genitourinary medications
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Genitourinary Drugs Market, by Indication
8.1. Introduction
8.2. Benign Prostatic Hyperplasia
8.3. Erectile Dysfunction
8.4. Interstitial Cystitis
8.5. Overactive Bladder
8.6. Urinary Tract Infection
9. Genitourinary Drugs Market, by Therapeutic Class
9.1. Introduction
9.2. 5 Alpha Reductase Inhibitors
9.3. Alpha Blockers
9.4. Anticholinergics
9.5. Beta3 Agonists
9.6. Combination Therapies
9.7. Pde5 Inhibitors
10. Genitourinary Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.4.1. Chain Pharmacies
10.4.2. Independent Pharmacies
11. Genitourinary Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. General Practice Clinics
11.2.2. Urology Clinics
11.3. Homecare
11.4. Hospitals
11.4.1. Secondary Care Centers
11.4.2. Specialty Clinics
11.4.3. Tertiary Care Centers
12. Genitourinary Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Injectable
12.3. Oral
12.4. Topical
13. Genitourinary Drugs Market, by Formulation
13.1. Introduction
13.2. Capsules
13.3. Injectable Solutions
13.4. Oral Solutions
13.5. Tablets
14. Genitourinary Drugs Market, by Sales Model
14.1. Introduction
14.2. Over The Counter
14.2.1. In-Store
14.2.2. Online
14.3. Prescription
15. Americas Genitourinary Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Genitourinary Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Genitourinary Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Pfizer Inc.
18.3.2. Astellas Pharma Inc.
18.3.3. AbbVie Inc.
18.3.4. Eli Lilly and Company
18.3.5. GlaxoSmithKline plc
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Ferring International Center S.A.
18.3.8. Teva Pharmaceutical Industries Ltd.
18.3.9. Johnson & Johnson
18.3.10. Merck & Co., Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. GENITOURINARY DRUGS MARKET: RESEARCHAI
FIGURE 30. GENITOURINARY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. GENITOURINARY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. GENITOURINARY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 162. CANADA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 163. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. CANADA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 166. CANADA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 167. CANADA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 168. CANADA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 169. CANADA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. CANADA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. CANADA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 172. CANADA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 173. CANADA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. CANADA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. CANADA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. CANADA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. CANADA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. CANADA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. CANADA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 180. CANADA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 181. CANADA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 182. CANADA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 183. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 190. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 191. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 192. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 193. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 204. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 205. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 305. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 308. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 309. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 312. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 313. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 314. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 315. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 318. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 319. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 320. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 321. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 322. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 323. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 324. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 325. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 326. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 327. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2024 (USD MILLION)
TABLE 328. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2025-2030 (USD MILLION)
TABLE 329. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. FRANCE

Samples

Loading
LOADING...

Companies Mentioned

  • Pfizer Inc.
  • Astellas Pharma Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Ferring International Center S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 41.54 Billion
Forecasted Market Value ( USD ) by 2030 $ 51.03 Billion
Compound Annual Growth Rate4.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Genitourinary Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Genitourinary Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 179 Pages
  • Global
From
Genitourinary Drugs Global Market Report 2025 - Product Image

Genitourinary Drugs Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Genitourinary Drugs - Global Strategic Business Report - Product Image

Genitourinary Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Genito-Urinary Drugs: Market Share, and Growth Analysis by Product Type (Antibiotics, Antispasmodics, Hormonal Therapies), Application, End User, Technology - Product Image

Genito-Urinary Drugs: Market Share, and Growth Analysis by Product Type (Antibiotics, Antispasmodics, Hormonal Therapies), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From

About the Genitourinary Drug Market

The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals. The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.